THE INFORMATION IN THE OBPHARMACOPOEIATM
IS INTENDED SOLELY FOR USE BY THE MEDICAL PROFESSION. IT IS NOT INTENDED FOR LAY PERSONS.
FOCUS INFORMATION TECHNOLOGY, INC. DOES NOT ASSUME ANY RESPONSIBILITY FOR ANY ASPECT OF
HEALTHCARE ADMINISTERED WITH THE AID OF THIS CONTENT. THE PRESCRIBING PHYSICIAN
MUST BE FAMILIAR WITH THE FULL PRODUCT LABELING AS PROVIDED BY THE MANUFACTURER AND RELEVANT MEDICAL LITERATURE PRIOR TO USING THE OBPHARMACOPOEIATM
.
ANTIVIRALS
Acyclovir(
Zovirax® )
Antiviral
- Acute Treatment of Herpes Zoster
800 mg every 4 hours orally, 5 times daily for 7 to 10 days.
- Initial Genital Herpes Simplex:
200 mg every 4 hours, 5
times daily for 10 days.
-
Chronic Suppressive Therapy for Recurrent Disease
400 mg 2 times daily for up
to 12 months, followed by re-evaluation.
Alternative regimens have included
doses ranging from 200 mg 3 times daily to 200 mg 5 times daily.
-
Intermittent Therapy
200 mg every 4 hours, 5 times daily for 5 days. Therapy
should be initiated at the earliest sign or symptom (prodrome) of recurrence.
-
Severe Disease (complicated disease -e.g. disseminated infection,
pneumonitis, hepatitis, meningitis or encephalitis)
5–10 mg/kg body weight IV every 8 hours for 2–7 days or until clinical
improvement is observed, followed by oral antiviral therapy to complete at least
10 days of total therapy [1].
- Chickenpox (Varicella-zoster)
Adults and Children over 40 kg: 800 mg 4 times daily for 5 days.
Adjust dose in patients with acute or chronic renal impairment
(200, 400, 800 mg tablets; 200 mg /5 mL suspension -Bottle of 1 pint -473 mL)
Breast feeding
LactMed
Famciclovir(Famvir®)
Antiviral
(125 , 250, 500 mg tablets)
Oseltamivir (Tamiflu
®) [2,3]
Antiviral, neuraminidase inhibitor
Adults
- Treatment of influenza
75-mg capsule orally twice per day for 5 days
- Chemoprophylaxis of influenza
75-mg capsule once per day for 10 days after the last close contact (within
6 feet) with a person who is a confirmed, probable or suspected case of novel
influenza A (H1N1) virus infection during the infectious period of the case.
Trivalent inactivated influenza vaccine can be administered at any time
relative to use of TAMIFLU
Dose adjustment is recommended for patients with a serum creatinine clearance
< 30 mL/min
(30, 45, 75 mg capsules; Available in blister packages of 10)
Valacyclovir
(Valtrex®)
Antiviral
- Acute Treatment of Herpes Zoster:
1
gram 3 times daily for 7 days. Therapy should be initiated at the earliest
sign or symptom of herpes zoster .
- Genital Herpes Initial Episode:
1 gram twice daily for 10 days. Therapy is most effective when administered within 48 hours of the onset of signs and symptoms.
-
Recurrent Genital Herpes Episodes:
500 mg twice daily for 3 days.
There are no data on the effectiveness of treatment with VALTREX when initiated more than 24 hours after the onset of signs or symptoms.
-
Chronic Suppressive Therapy:
1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily. The safety and efficacy of therapy with VALTREX beyond 1 year have not been established.
-
In HIV-infected patients with CD4 cell count ³100 cells/mm3
500 mg twice daily. The safety and efficacy of therapy with VALTREX beyond 6 months in patients with HIV infection have not been established.
-
Reduction of Transmission in patients with a history of 9
or fewer recurrences per year:
500 mg once daily for the source partner. The efficacy of reducing transmission beyond 8 months in discordant couples has not been established.
- Cold Sores (Herpes Labialis):
2 grams twice daily for 1 day taken 12 hours
apart. Therapy should be initiated at the earliest symptom of a cold sore.
Adjust dose in patients with acute or chronic renal impairment
(500 mg, 1 gram caplets)
Zanamivir (Relenza
®)
Antiviral, neuraminidase inhibitor
Adults
- Treatment of influenza
Two 5-mg inhalations (10 mg total) twice per day
- Chemoprophylaxis of influenza
Two 5-mg inhalations (10 mg total) once per day for 10 days
after the last close contact (within 6 feet) with a person who is a
confirmed, probable or suspected case of novel influenza A (H1N1) virus
infection during the infectious period of the case.
(5 mg blisters of powder on a ROTADISK for oral inhalation via DISKHALER.
Packaged in carton containing 5 ROTADISKs (total of 10 doses) and 1 DISKHALER
inhalation device)
REFERENCES;
1.
CDC Sexually Transmitted Diseases Treatment
Guidelines , 2006
MMWR August 4, 2006/ 55 (RR-11)'
2. Interim Guidance on Antiviral Recommendations for Patients with Novel
Influenza A (H1N1) Virus Infection and Their Close Contacts.
http://www.cdc.gov/h1n1flu/recommendations.htm Accessed 7-19 3.Tanaka
T, et al "Safety of neuraminidase inhibitors against novel influenza A (H1N1) in
pregnant and breastfeeding women" CMAJ 2009; DOI:10.1503/cmaj.090866. Accessed
7-19-09 |